The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
"The charts, as interpreted by Carley Garner, suggest that the upside in the stock market has gotten more limited," Jim Cramer says.Mad Money with Jim Cramerread more
U.S. President Donald Trump said Tuesday that Washington and Beijing have a long way to go on trade, adding that America could place tariffs on an additional $325 billion...Asia Marketsread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
Delta is gathering more data from customers than ever in hopes of avoiding customer service problems and increasing customer satisfaction, its CFO says.At Workread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Bristol-Myers Squibb said its blockbuster immunotherapy, Opdivo, failed to improve survival in previously untreated patients with a form of lung cancer, without their disease progressing.
Bristol-Myers' shares were down 20 percent at $60 in premarket trading. Shares of Merck & Co, which makes rival drug Keytruda, were up 11 percent at $64.60.
The trial was testing Opdivo against chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Opdivo, first approved in late 2014, is already approved for use in NSCLC patients who have failed prior therapy, as well as forms of melanoma, kidney cancer and blood cancer.
— CNBC contributed to this report.